Trimeris (TRMS) Receives Non-Compliance Notification From NASDAQ
More News related to TRMS
- Stull, Stull & Brody Announces Investigation on Behalf of Shareholders of Trimeris, Inc.
- Law Offices of Howard G. Smith Announces Class Action on Behalf of Shareholders of Trimeris, Inc.
- Law Offices of Howard G. Smith Announces Investigation On Behalf of Shareholders of Trimeris, Inc.
- Trimeris (TRMS) Acquired by Arigene Co. for $3.60/Share in Cash
- Arigene Co., Ltd. Commences Tender Offer to Acquire All Outstanding Shares of Trimeris, Inc. Stock for $3.60 Per Share in Cash
More News related to Corporate News
- XOMA (XOMA) Falls Modestly Following After-Hours Downgrade
- Morgan Stanley Upgrades CHU to Overweight, Downgrades CHL, CHA to Equal Weight
- Natixis Bleichroeder Downgrades Tenaris S.A. (TS) to Reduce
- Bank of America Downgrades Seneca Foods (SENEB) from Buy
- RBC Downgrades Intrepid Potash (IPI) to Sector Perform
Trimeris, Inc. (Nasdaq: TRMS) received a Nasdaq Staff Deficiency Letter stating that the Company was not in compliance with the Nasdaq audit committee requirement for continued listing as set forth in Marketplace Rule 4350 due to the resignation on December 15, 2008 of Director Kevin C. Tang. At the time of his resignation, Mr. Tang served on the Company's audit committee. His resignation was previously announced by the Company on a Form 8-K filed with the Securities and Exchange Commission on December 16, 2008.
Trimeris, Inc. is a biopharmaceutical company engaged in the commercialization of therapeutic agents for the treatment of viral disease. [SM]
Related Categories
Corporate NewsStocks Mentioned
+0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
